Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice
AUTOR(ES)
Gladstone, David J.
RESUMO
TISSUE PLASMINOGEN ACTIVATOR (TPA) INJECTED INTRAVENOUSLY within 3 hours of symptom onset has emerged as a treatment option for acute ischemic stroke. Although controversial and not universally accepted, its use in carefully selected patients is supported by evidence from randomized controlled trials and by mounting community experience. In this paper we review the literature published in the past 5 years regarding the safety, clinical trial efficacy and real-world effectiveness of intravenous tPA for stroke. First we review data from the phase III clinical trials on which approval for tPA is based. Then we summarize a growing literature of postmarketing phase IV studies and discuss the limitations and challenges that lie ahead. Our aim is to provide clinicians with an overview of this evolving therapy.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=81334Documentos Relacionados
- Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study
- BOOK REVIEWS: Stroke: Populations, Cohorts, and Clinical Trials.
- Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials.
- Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials.
- Intravenous thrombolytic therapy for acute ischemic stroke: clinical experience of department of neurology of the Hospital das Clínicas da Universidade de São Paulo